Search results
4 days ago · JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st.
5 days ago · JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st.
4 days ago · Massachusetts Wealth Management increased its stake in shares of Eli Lilly and Company ( NYSE:LLY – Free Report) by 20.1% in the 1st quarter, according to its most recent 13F filing with the ...
4 days ago · Eli Lilly Revenue. Eli Lilly had revenue of $35.93B in the twelve months ending March 31, 2024, with 29.76% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $8.77B with 25.98% year-over-year growth. In the year 2023, Eli Lilly had annual revenue of $34.12B with 19.56% growth.
13 hours ago · Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk A/S NYSE: NVO, best known for Ozempic and Wegovy. By all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is ...
4 days ago · Check out our LLY stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.
4 days ago · July 5, 2024. Eli Lilly and Company ( NYSE:LLY - Get Free Report) shares rose 1.2% during trading on Friday . The stock traded as high as $909.27 and last traded at $908.58. Approximately 817,968 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 2,930,744 shares. The stock had previously closed at ...
